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Abstract
Background: It is not clear if all Americans have benefitted equally from the
availability of chimeric antigen receptor T-cell (CART) therapy. We aimed to
evaluate if demographic differences existed among adult patients who received
CART therapy and to assess predictors of CART treatment outcomes.
Methods: Records of patients ≥18 years who received CART therapy for non-
Hodgkin’s lymphoma, acute lymphoblastic leukemia, and multiple myeloma in
2018 were evaluated in the National Inpatient Sample. Acute complications and
inhospital mortality were compared between two groups of CART recipients:
Whites and non-Whites. Logistic regression analysis was used to evaluate the association between sociodemographic factors and inhospital mortality.
Results: Of 1275 CART recipients that met inclusion criteria, there were 40.4%
of females, 66.9% of Whites, Blacks (4.2%), Hispanics (13.3%), Asians or Pacific
Islanders (4.2%), and Native Americans (1.3%). Up to 96.8% of CART procedures
were performed in urban teaching hospitals, and 85.3% of CART recipients lived
in metropolitan counties. Non-Whites, compared to Whites, were younger at the
time of CART therapy (p < 0.001). The inhospital mortality rate was higher in
non-Whites, though not statistically significant (5.4% vs. 4.4%, p = 0.764). There
were no differences in length of hospital stay, hospital charges, or rates of acute
toxicities between the two race groups. We found no association between race
and treatment outcomes. Gender, neurotoxicity, and Charlson Comorbidity
Index were significant predictors of inhospital mortality.
Conclusions: CART therapy recipients in the United States were more likely to
be Whites and more likely to be residents of metropolitan areas. These observed
demographic differences were not associated with treatment outcomes or inhospital mortalities.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided
the original work is properly cited.
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Cancer Medicine. 2022;00:1–9.		

wileyonlinelibrary.com/journal/cam4

|

1

2

|

EMOLE et al.

  

KEYWORDS

CART cell therapy, disparities, leukemia, lymphoma, multiple myeloma, sociodemographic
factors

1

|

I N T RO DU CT ION

Chimeric antigen receptor T-
cell (CART) therapy is
an adoptive cellular therapy used for the treatment of
chemotherapy-
refractory hematological malignancies.
Most of the CART therapies currently in use are produced
from autologous T cells obtained from patients by apheresis, genetically modified to target a specific tumor antigen,
expanded, cryopreserved, and eventually infused back
into patients. Prior to infusion of CART cells, patients
may receive lymphodepleting chemotherapy. While cytokine release syndrome and neurotoxicity are common
toxicities following CART infusion1, other longer term
complications include cytopenia and B-cell aplasia with
hypogammaglobulinemia. CART therapy is associated
with considerable financial costs, irrespective of the site
of administration—inpatient or ambulatory settings.2–4
The availability of CD19-directed CART has led to impressive response rates for patients with relapsed/refractory B lymphomas. In the ZUMA-1 trial, which evaluated
the efficacy of axicabtagene ciloleucel in 111 patients
with refractory diffuse large B-cell lymphoma (DLBCL),
primary mediastinal B-
cell lymphoma, or transformed
follicular lymphoma, the investigators reported an objective response rate of 82% (complete response rate of 54%).
With a median follow-up of 15.4 months, a 40% complete
response rate was observed.5 Tisagenlecleucel was evaluated in a multicenter phase 2 study for adult patients with
relapsed or refractory DLBCL who were ineligible for or
had disease progression after autologous hematopoietic
stem cell transplantation. After a median follow-up of
14 months, an overall response rate of 52% was observed
(40% had complete responses, while 12% had partial responses).6 Another CART product (lisocabtagene maraleucel) was evaluated in the TRANSCEND trial for adult
patients with relapsed or refractory large B-cell lymphoma
(DLBCL, double-
hit or triple-
hit lymphoma, DLBCL
transformed from any indolent lymphoma, primary mediastinal B-cell lymphoma, or follicular lymphoma grade
3B). The authors reported an objective response rate of
73%, with 53% of patients achieving a complete response.7
In addition to currently approved indications in high-
grade B-cell lymphomas, CART therapies have been approved for B-cell acute lymphoblastic leukemia, mantle
cell lymphoma, follicular lymphoma, and multiple myeloma.8–12 While there are currently no approved CART products for other hematological disorders, these therapies are

being evaluated for CLL,13–15 Hodgkin's lymphoma16–18,
and AML.19–21 Beyond autologous CART therapies, allogeneic CART cells obtained from healthy donors and genetically edited to target respective antigens are actively
being evaluated.22
Despite the remarkable responses observed in CART
therapy for hematological malignancies, these outcomes
may not be experienced equally by all Americans. In the
United States (US), it is known that certain populations
suffer health disparities more than others.23 Minority
populations (Asians, American Indians, Alaskan Natives,
Hispanics, and Blacks) have been known to experience
poorer health compared to their Caucasian counterparts.24,25 Persons without health insurance have a lower
likelihood of having an usual source of health care, preventative care, and management of chronic conditions,26
while patients who are uninsured or underinsured at the
time of diagnosis of cancer are more likely to die in 5 years
compared to patients with private insurance.26 For hematological malignancies, racial and socioeconomic factors have been found to affect access to and outcomes of
treatment.27
Very few studies have evaluated the effect of sociodemographic characteristics on the receipt and outcomes of
CART therapy for adult patients with hematological disorders. Initial data from the Center for International Bone
Marrow Transplant Research (CIBMTR) on CART utilization show that minority groups were underrepresented
among recipients of CART therapies for hematological disorders.28 A pediatric real-world consortium data showed
that African American children were less likely to undergo
CART therapy (even after apheresis) and had poorer outcomes after CART therapy.29 Since these studies were not
specific to the adult CART population, it is not clear how
much their conclusions could be extrapolated to adult recipients. To effectively evaluate CART receipt among adults
in the US and inform interventions that will address any
gaps and disparities, dedicated studies of CART utilization
patterns and outcomes have become necessary.
Our study aimed to evaluate if demographic differences
existed among patients that received CART therapy for
non-Hodgkin lymphoma, multiple myeloma, and acute
lymphoblastic leukemia—three disease groups with the
most frequent CART use in recent years.28 This study also
sought to compare CART treatment outcomes between
racial groups and evaluate the association of sociodemographic characteristics and inhospital mortality.
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Data source

For this study, we used data from the National Inpatient
Sample (NIS). The NIS is the largest publicly available
all-payer inpatient care database in the US and provides
regional and national estimates of inpatient utilization,
charges, quality, and outcomes. As a stratified sample, the
NIS contains 20% (over 7 million) of all discharges from
nonfederal acute care hospitals for the year 2018. When
weighted, it estimates more than 35 million hospitalizations in the US. The 2018 NIS sampling frame includes
data from 48 statewide data organizations (47 states plus
the District of Columbia).30 Each discharge record in the
NIS contains patient-level data (demographics, diagnoses,
procedures, insurance, discharge, total hospital charges,
and length of hospital stay) as well as hospital-level data
(geographic region, location, teaching status, bed size,
and ownership). All data in the database are de-identified
and compliant with the Health Insurance Portability and
Accountability Act.
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Ethics approval statement

Prior to commencing this study, ethical approval was
sought from the Institutional Review Board of Henry Ford
Hospital, Detroit, Michigan, and the study received an exemption determination.
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Study design

From the NIS database, we selected and included all hospitalization records for patients 18 years or older, who
underwent CART therapy for acute lymphoblastic leukemia (ALL), multiple myeloma (MM), or non-Hodgkin's
lymphoma (NHL) from January 2018 to December 2018.
The year 2018 was selected for analysis, being the first full
year after CART became available for commercial use.
Hospitalization records for patients who received CART infusions without a diagnosis of MM, NHL, or ALL were excluded from the analysis. The International Classification
of Disease, Tenth Revision (ICD-10) procedure codes for
autologous CART immunotherapy were used to identify
CART procedures. ALL, MM, and subtypes of NHL were
identified using their respective ICD-10 diagnostic codes.
Our study was limited to autologous CART products, and
the study design did not make a distinction between first
and subsequent CART procedures. Additionally, our study
did not differentiate between commercially available and
investigational CART products.
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Patient-level data extracted from eligible hospital records were age, gender, race, hematological disorders,
insurance, income, location of patients’ residence, and
patient comorbidities. Hospital level characteristics of
interest were hospital geographical location and teaching
status. Charlson Comorbidity Index was used as a summary measure of patients’ comorbidities. Income was represented by the median household income quartiles for
the patient’s zip code. The location of patients' residences
was assessed by the National Center for Health Statistics
(NCHS) urban–rural classification scheme for counties
in the United States. Counties in areas with a population ≥50,000 were considered metropolitan (urban). For
metropolitan areas of ≥1 million population, the “fringe”
counties were designated as suburban counties. Counties
in areas of <50,000 population were designated nonmetropolitan (rural).
The primary study outcome was CART utilization
patterns across the US. Secondary outcomes were inhospital mortality and rates of acute CART treatment
complications (hemophagocytic lymphohistiocytosis,
neurotoxicity, sepsis, acute kidney injury, fever, and respiratory failure). Assignment of neurotoxicity was guided
by the consensus grading for neurological toxicity by
the American Society for Transplantation and Cellular
Therapy.1 Sociodemographic factors, comorbidities, CART
treatment complications, and hospitalization outcomes
were compared between two groups of CART recipients:
Whites and non-Whites (Black, Hispanic, Asian, Pacific
Islander, Native American, and others).

2.4
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Statistics

Clinical variables were summarized using counts and proportions for categorical data and median and interquartile
ranges for continuous data. In compliance with the NIS
data use agreement, categories were combined, and some
data were suppressed to avoid reporting any cell counts
less than or equal to 10. Since the NIS is a stratified sample, appropriate weights were applied to the analyses to
obtain national estimates. All variables were checked for
missing data, and frequencies of missing data were reported. Chi-squared (χ2) test was used to compare categorical variables, while continuous variables were compared
between race groups (White vs. non-White) using the
Wilcoxon rank-sum test. Prior to statistical modeling, the
distribution of missing data was reported, and the multiple imputation method31 was used to impute missing data,
resulting in a database with no missing data. Race had the
highest level of missingness (5.5%). Regression methods
were used to evaluate the association between patient
sociodemographic factors and inhospital mortality, and
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odds ratio (OR) with 95% confidence intervals (CI) was
reported. Potential confounders such as location of residence, insurance, age, gender, and comorbidity index
were controlled for. All tests were two sided, and the results were considered significant at an alpha level of 5%
(p < 0.05). Stata version 16 (StataCorp) was used for statistical analysis.
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R E S U LTS

3.1 | Baseline patient and treatment
characteristics
Of the 1425 autologous CART infusions identified in the
database for the year 2018, 1275 met the inclusion criteria
for our study. The analytic population (N = 1275) consisted of adults aged 18–82 years, of whom 515 (40.4%)
were female. The sociodemographic and clinical characteristics of the CART recipients are stratified by cancer
diagnosis; acute lymphoblastic leukemia (ALL)[n = 115],
multiple myeloma (MM)[n = 200], and non-Hodgkin's
lymphoma (NHL)[n = 960] are presented in Table 1. The
median age of patients was 59 years with an interquartile
range of 18 years. Patients older than 70 years comprised
10.2% of the study population. CART recipients included
Whites (66.9%), Blacks (4.2%), Hispanics (13.3%), Asians
or Pacific Islanders (4.2%), Native Americans (1.3%), and
others (10%). Non-
Hodgkin's lymphoma (diffuse large
B-cell lymphoma) was the most common indication for
CART treatment in the year 2018. Primary payer was
private insurance for 752 (59%) patients, Medicare for
337(26.4%), and Medicaid for 129(10.1%) patients. With
regard to acute CART toxicities, neurotoxicity was reported in 395 (30.9%) patients, sepsis in 130 (10.2%), acute
kidney injury in 180 (14.1%), fever in 630 (49.4%), respiratory failure requiring mechanical ventilation in 80 (6.3%),
and hemophagocytic lymphohistiocytosis in 15 (1.2%)
patients.

3.2 | Comparison of clinical variables
between racial groups
Due to the low number of patients in some racial/ethnic
groups and in compliance with the data use agreement,
this study combined all minority racial/ethnic groups, so
that comparisons were focused on two groups: Whites and
non-White (Black, Hispanics, Pacific Islanders, Asians,
Native Americans, and others). In Table 2, we present the
comparison of select variables between CART recipients,
by race. Non-Whites, compared to Whites, were younger
at the time of CART therapy (median age 56 years vs.

61 years, p < 0.001) and had higher Charlson Comorbidity
Index score (49.5% vs. 36.7%, P = 0.021). Whites were
more likely to live in nonmetropolitan counties compared
to non-Whites (17.1% vs. 10.4%, p = 0.040). While the proportion of patients with private insurance was similar between the two groups, Whites were twice more likely to
have Medicare (33.1% vs. 15.4%, p < 0.001). Inpatient mortality was 4.7% (60 patients) and was comparable for both
groups. The median length of hospital stay for the entire
cohort was 15 days (range 3–112 days) and did not differ
between the two groups (15 days for Whites and 16 days
for non-Whites, p = 0.204). Gender, median total hospital charges, and rates of acute complications were not significantly different for Non-Whites compared to Whites.
The rate of discharge disposition to short-term hospitals,
skilled nursing facilities, or intermediate care facilities
was 6.8% for Whites and 3.2% for non-Whites, p = 0.124.

3.3 | Bivariable and
multivariable analyses
In Table 3, we present the results of select predictors of
inhospital mortality (unadjusted and adjusted odds ratios). In the unadjusted model, the significant predictors
of inhospital mortality were neurotoxicity and Charlson
Comorbidity index ≥3. Race, insurance type, income, and
gender did not show any significant association with inhospital mortality. After adjusting for potential confounders,
gender, neurotoxicity, and Charlson Comorbidity index
≥3 were predictors of inhospital mortality. Compared to
patients with Charlson Comorbidity of 0–2, those with
an index ≥3 had about five times higher odds of mortality
(OR = 5.09, 95% CI: 1.71–15.13, p = 0.004). Similarly, the
presence of neurotoxicity was associated with higher odds
of mortality (OR = 14.05, 95% CI: 4.20–46.96, p < 0.001),
while females had a 72% lower likelihood of death compared to males (OR = 0.28, 95% CI: 0.12–0.68, p = 0.005).
No association was found between sociodemographic factors and acute toxicities, length of hospital stay, or total
hospital charges.
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Our study represents one of the first and largest inquiries into the patterns of CART use for adults in the United
States (US). In this retrospective study of patients who received CART therapy in the inpatient setting in 2018, we
demonstrate that patients of minority racial/ethnic groups
(especially Blacks) were underrepresented in CART use
for the treatment of non-
Hodgkin's lymphoma, acute
lymphoblastic leukemia, and multiple myeloma. We also
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T A B L E 1 Demographic and clinical
characteristics of hospitalized CART
recipients (NHL, ALL, and MM) in 2018

Characteristics n (%)

|

NHL

ALL

MM

All patients

960 (75.3)

115 (9.0)

200 (15.7)

1275 (100.0)

60 (14.5)

23 (6)

59 (10)

59 (18)

385 (40.1)

60 (52.2)

70 (35.0)

515 (40.4)

Whites

666 (69.4)

46 (40)

142 (71.1)

853 (66.9)

Blacks

21 (2.2)

S

32 (15.8)

54 (4.2)

Hispanics

99 (10.4)

52 (45)

21 (10.5)

169 (13.3)

Asian or Pacific Islander

53 (5.5)

S

S

54 (4.2)

Native American

11 (1.1)

S

S

17 (1.3)

Others

110 (11.5)

S

S

128 (10.0)

Central counties of metro areas of
≥1 million

270 (28.1)

36 (31.8)

92 (46.2)

395 (30.9)

Fringe counties of metro areas of
≥1 million population

228 (23.8)

42 (36.4)

72 (35.9)

343 (26.9)

Counties in metro areas of 250,000– 213 (22.2)
999,999 population

16 (13.6)

21 (10.3)

250 (19.6)

Counties in metro areas of 50,000–
249,999 population

83 (8.7)

S

S

100 (7.8)

Nonmetropolitan (<50,000
population)

166 (17.3)

S

S

187 (14.7)

$1–$45,999

146 (15.2)

42 (36.4)

15 (7.7)

204 (16.0)

$46,000–$58,999

225 (23.4)

31 (27.3)

36 (18.0)

292 (22.9)

$59,000–$78,999

324 (33.7)

26 (22.7)

67 (33.3)

418 (32.7)

$79,000 or more

265 (27.7)

16 (13.6)

82 (41.0)

361 (28.3)

1–2

545 (56.8)

65 (56.5)

140 (70.0)

748 (58.7)

≥3

415 (43.2)

50 (43.5)

60 (30.0)

527 (41.3)

Northeast

290 (30.2)

15 (13.1)

90 (45.0)

396 (31.1)

Midwest

205 (21.4)

15 (13.0)

15 (7.5)

236 (18.5)

South

265 (27.6)

30 (26.1)

35 (17.5)

332 (26.0)

West

200 (20.8)

55 (47.8)

60 (30.0)

311 (24.4)

935 (97.4)

115 (100)

190 (95)

1234 (96.8)

Total
a

Age in years, median (IQR)

5

Gender
Female (%)
Race

Location of patient's residence

Median household income

Charlson Comorbidity Index

Hospital Location (US region)

Hospital type
Urban teaching hospital

Abbreviations: NHL, Non-Hodgkin's lymphoma; ALL, acute lymphoblastic leukemia; MM, multiple
myeloma; HMO, health maintenance organization; US, United States; S, suppressed data, IQR,
Interquartile Range.
a

Median (IQR) reported.

demonstrate that a majority of CART therapies were performed in teaching hospitals located in urban areas, and
that most CART therapy recipients were urban dwellers.
Inhospital mortality following CART therapy was low,
and we found no association between race or ethnicity
and CART acute outcomes (mortality, toxicity, and resource use).

Non-Hispanic Whites constituted most of the CART
recipients in our study, consistent with reports from the
Center for International Blood and Marrow Transplant
Research (CIBMTR). In the CIBMTR analysis of all
CART infusions performed in the US from 2016 to 2019
(2058 patients), 81% were Caucasians, while Asians
and African Americans were 4% and 5%, respectively.28
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TABLE 2

Comparison of select variables between CART recipients in 2018

Variable
a

Age in years median (IQR)

White (%)

Non-white (%)

p

61 (13)

56 (24)

< 0.001

Location of patient's residence

0.04

Central counties of metro areas of > = 1 million population

23.42

44.83

Fringe counties of metro areas of > = 1 million population

31.65

18.39

Counties in metro areas of 250,000–999,999 population

20.25

18.39

Counties in metro areas of 50,000–249,999 population

07.59

08.05

Nonmetropolitan (<50,000 population)

17.09

10.35

37.27

46.24

63.35

50.54

Female
Charlson Comorbidity Index
0–2

0.254
0.021

36.65

49.46

04.35

05.38

0.737

06.83

03.23

0.124

Hemophagocytic lymphohistiocytosis

01.18

01.86

0.140

Neurotoxicity

30.43

32.26

0.729

≥3
Inhospital mortality
b

Discharge to other facilities

Acute CART treatment complications

Sepsis

11.8

07.53

0.224

Acute kidney injury

12.42

17.2

0.308

Fever

49.69

49.46

0.978

Respiratory failure

06.21

06.45

0.935

Length of stay in days (median, days)

15

16

0.204

Total charges (median, US dollars)

537,281

493,887

0.521

IQR, Interquartile Range.
a

Median (IQR) reported.

b

Short-term hospital, skilled nursing facility, intermediate care facilities.

An updated report from the CIBMTR continues to show
a similar pattern for CART recipients from 2016 to 2021
(4094 patients, 78% non-Hispanic Caucasians).32 Put together, these findings indicate that people of minority
racial or ethnic origins are poorly represented in CART
receipt in the United States, and based on the aforementioned CIBMTR reports, the trend has not significantly
improved since 2016.
Racial disparity in CART receipt in our study affected
Blacks more disproportionately compared to other minority racial groups. When the findings of our research are
juxtaposed with the US census demographic data33 and
prevalence and incidence data (Tables 4 and 5), receipt
of CART therapies by Blacks is markedly low compared
to their proportion of the US racial makeup and disease
burden. While Blacks constituted 13.4% of the US population in 2019, only 4.2% of the total CART recipients in
our study were reported to be Blacks. And, while multiple
myeloma is 2–3 fold more common in African Americans
compared to Caucasians,34–36 Blacks constituted only
15.8% of CART recipients for multiple myeloma in our
study (compared to 71.1% Whites). A similar pattern was

observed by the Pediatric Real World CAR Consortium,
which reported that in a cohort of 200 recipients of tisagenlecleucel for relapsed and refractory ALL, only 5.5%
were Blacks.29 Not only were Blacks and Asians poorly
represented in the Pediatric Real World CAR Consortium
study, but also Blacks were disproportionately represented
among patients who were not infused with the CART
product (36.4% of Blacks were not infused compared to
5.8% of patients of other races).
While we found no differences in CART use patterns
for the geographical regions of the US, we observed from
our data that CART therapy was predominantly performed in teaching hospitals located in urban centers.
This pattern is not surprising since CART infusions and
subsequent care require subspecialty expertise and multidisciplinary care that are mostly available in large cancer
centers. Subsequently, patients who live far from these
teaching hospitals will likely experience poor access to
CART treatments. In a retrospective evaluation of adult
CART recipients from 2018 to 2020, Ahmed et al. found
a relationship between patients' distance from the CART
center, household income, and likelihood to undergo

EMOLE et al.
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Select predictors for inhospital mortality

Variable

Unadjusted OR

CI

Adjusted OR

CI

Female (versus Male)

0.47

0.16–1.41

0.28

0.12–0.68

White (versus non-white)

0.80

0.22–2.95

0.68

0.12–3.96

CCI ≥3(versus CCI 0–2)

4.24

1.69–12.32

5.09

1.71–15.13

Location of patient's residence
Central countries of metro areas of ≥1 million population

Ref

Ref

Fringe counties of metro areas of ≥1 million population

1.56

0.52–4.79

1.30

0.31–5.55

Counties in metro areas of 250,000–999,999 population

1.06

0.23–4.79

0.40

0.06–2.69

Counties in metro areas of 50,000–249,999 population

1.35

0.14–13.50

0.42

0.06–2.89

1.43

0.11–6.77

0.31

0.03–3.13

7.37

1.99–27.27

14.05

4.20–46.96

Non-metropolitan areas (<50,000 population)
Neurotoxicity (versus no neurotoxicity)

OR, odds ratio; CI, confidence interval; CCI, Charlson Comorbidity Index; Ref, reference category.

T A B L E 4 Incidence rates, by race/ethnicity, 2013–2017, SEER
21 (rates per 100,000 population)

T A B L E 5 Approximate United States prevalence of blood
cancers, by race/ethnicity, as of January 1, 2017

NHL

ALL

MM

NHL

ALL

MM

White (non-hispanic)

21

1.6

6.3

White (non-hispanic)

541,634

42,981

93,963

Black

14.7

1.0

13.8

Black

54,040

5238

28,309

Hispanic

18.1

2.5

6.8

Hispanic

54,782

19,802

11,018

Asian/Pacific Islander

13.5

1.5

3.9

Asian/Pacific Islander

21,124

3465

3843

American Indian/Alaskan
Native

10.9

1.6

5.7

American Indian/
Alaskan Native

1742

576

605

Source: Facts 2020–2021 and Cancer Facts & Figures 2021, American Cancer
Society, 2021 and Surveillance, Epidemiology, and End Results Program.

Source: Facts 2020–2021 and Cancer Facts & Figures 2021, American Cancer
Society, 2021 and Surveillance, Epidemiology, and End Results Program.

NHL, Non-Hodgkin's lymphoma; ALL, acute lymphoblastic leukemia; MM,
multiple myeloma; SEER, Surveillance, Epidemiology, and End Results.

NHL, Non-Hodgkin's lymphoma; ALL, acute lymphoblastic leukemia; MM,
multiple myeloma.

CART. In their analysis, the authors noted that patients
who live greater than 60 miles from a CART center were
less likely to undergo CART, especially if they lived in
neighborhoods with a median income of <$40,000. The
authors concluded that patients' residence location relative to the CART center (and their household income) influences CART access.37
The US Census Bureau estimates that about 19% of
the US population lives in rural areas.38 But our study revealed that across disease types, only 14.7% of CART recipients were residents in rural areas. For multiple myeloma,
in particular, CART recipients were almost exclusively
residents of metropolitan counties (areas with population ≥50,000). The lower representation of rural residents
in CART may be due to lower access to care, higher travel
distance, and higher health-related financial burdens compared to urban dwelling residents. Since all CART therapies for multiple myeloma in 2018 were given within the
context of clinical trials, the extremely low representation
of rural dwellers in receipt of CART for multiple myeloma
calls for improved access of rural dwellers to clinical trials.
With the current shortages of physicians, oncologists, and

specialty cancer centers in rural America,39,40 it is likely
that rural dwellers may continue to experience a lack of
access to CART therapies in the near future.
Even though racial and rural–urban disparities were
noted in CART patterns of use, we found no association
between race or residence and outcomes of CART treatment hospitalization. Inpatient mortality was relatively
low, and acute CART toxicities were similar to rates reported in current literature. Even though persons of minority origin had a higher comorbidity burden compared
to Whites, both groups had similar rates of acute CART
complications and mortality. Resource utilization was also
not significantly different between the two groups. Some
studies have shown rural–
urban disparities in health
41–43
and all-cause mortality,
but we found no association
between residence in the metropolitan areas and CART
treatment outcomes. Compared to other urbanization
areas, residents in the suburbs did not predict CART treatment outcomes.
Our study is limited by its retrospective nature. Since the
NIS database lacks imaging and laboratory details, we relied on ICD-10 codes to define acute CART complications.
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As such, our estimates of some acute CART toxicities may
be lower than expected. Secondly, ICD-10 codes for cytokine release syndrome did not exist in 2018, and we could
not provide estimates of cytokine release syndrome from
our data. Finally, our study evaluated CART therapies administered in the inpatient setting, but we have no reason
to believe that our results would be significantly different
if outpatient CART therapies were included in our analysis. Despite these few limitations, our analysis sets the
stage for larger and prospective studies that would critically evaluate disparities in CART therapy use in the US.
In conclusion, this retrospective analysis of a large national inpatient database evaluated the patterns of CART
therapy use across sociodemographic groups in the US
and found that adults of minority racial origin were underrepresented in CART use. Racial disparity in CART use
was more pronounced for Blacks. Americans living outside metropolitan areas were less likely to receive CART
therapy. The extremely low inclusion of nonmetropolitan
residents in CART receipt for multiple myeloma emphasizes the need to make CART therapies and clinical trials
available beyond urban teaching hospitals. Our analysis
revealed equivalent hospitalization outcomes irrespective
of patients’ race or residence.
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